View up-to-date information on Samsung Biologics Co Ltd’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| January 27, 2022 | Samsung Biologics Acquires Remaining Stake in Samsung Bioepis from Biogen | Acquisition | Samsung Biologics Co Ltd | Samsung Bioepis Co Ltd |
| August 13, 2020 | Samsung Bioepis Co Ltd Enters Phase I Clinical Trial Agreement with Parexel International Corp for adalimumab biosimilar (GDCT0396216) | Contract Service Agreement | Samsung Bioepis Co Ltd;Samsung Bioepis Co Ltd | Parexel International Corp;Parexel International Corp |
| June 23, 2020 | Samsung Bioepis Co Ltd Enters Phase III Clinical Trial Agreement with Parexel International Corp for aflibercept biosimilar (GDCT0386792) | Contract Service Agreement | Samsung Bioepis Co Ltd;Samsung Bioepis Co Ltd | Parexel International Corp;Parexel International Corp |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer